Foresight Diagnostics Showcases Ultrasensitive MRD Technology in Multiple Lymphoma Studies at ASH 2025
核心洞察
Foresight Diagnostics (搜索) will present multiple lymphoma studies featuring their PhasED-Seq ultrasensitive minimal residual disease (MRD) analysis at the 67th ASH Annual Meeting in Orlando, Florida.
The presentations reflect growing integration of circulating tumor DNA-based MRD testing into clinical studies across hematologic malignancies, moving beyond feasibility studies into clinical trial frameworks.
Academic groups and pharmaceutical partners are increasingly deploying MRD prospectively within MRD-guided trial designs, exploratory endpoints, and therapeutic development programs.
Foresight Diagnostics (搜索), a leader in ultrasensitive minimal residual disease (MRD) detection technology, announced multiple lymphoma study presentations featuring their Foresight CLARITY (PhasED-Seq) MRD analysis at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida.
The presentations demonstrate the growing integration of highly sensitive, circulating tumor DNA (ctDNA)-based MRD testing into clinical studies across hematologic malignancies. Academic groups and pharmaceutical partners are increasingly deploying MRD not only for retrospective assessment but also prospectively within MRD-guided trial designs, exploratory endpoints, and therapeutic development programs.
Clinical Applications Expanding Beyond Feasibility Studies
"Across industry and academic collaborators, we're seeing a meaningful shift in how ctDNA-MRD is being used in lymphoma," said David Kurtz, MD, PhD, Chief Medical Officer and Co-founder of Foresight Diagnostics (搜索). "Ultrasensitive MRD analysis is moving beyond feasibility studies and into clinical trial frameworks, where molecular response has the opportunity to inform patient care decisions. At Foresight Diagnostics, we're proud to support this next phase of MRD-driven innovation in lymphoma."
Key Study Presentations at ASH 2025
The company's PhasED-Seq technology will be featured in several notable presentations on Saturday, December 6. Mark Roschewski, MD from NCI/NIH will present findings from a response-adapted Phase 2 study examining acalabrutinib window prior to frontline chemotherapy in untreated large B-cell lymphoma, focusing on molecular correlates of response to acalabrutinib.
Swetha Thiruvengadam, MD from City of Hope will deliver an oral presentation on a first-in-human, open-label Phase 1 study of PF-08046044 (35C), a novel CD30 (搜索)-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload in patients with relapsed/refractory lymphomas. The presentation will include updated safety, pharmacokinetic data, preliminary efficacy results, and ctDNA analysis from dose escalation.
Jordan Goldstein, MD, MSc from Stanford University will present research on spatial anatomical genomic heterogeneity and aberrant somatic hypermutation that define clonal evolution pathways predicting treatment resistance in aggressive B-cell lymphomas.
Technology Integration in Therapeutic Development
The presentations reflect the broader trend of integrating ultrasensitive MRD analysis into various aspects of lymphoma research and treatment development. The technology is being incorporated into both academic research initiatives and pharmaceutical development programs, indicating its growing acceptance as a valuable tool for monitoring treatment response and guiding clinical decisions.
Foresight Diagnostics (搜索) will be available for meetings at booth #2165 during the ASH Annual Meeting, with additional contact available through BD@foresight-dx.com for those interested in learning more about their MRD detection capabilities.